Veradermics Q2 net loss widens on higher expenses

Veradermics, Incorporated

11/08/2026 12:40

Overview
Biopharmaceutical developer reported Q2 net loss widened yr/yr amid higher R&D and G&A expenses
Cash position rose to $819.9 mln at June 30, 2026, expected to fund operations into 2030

Outlook
Company expects topline data from Phase 3 Study '304' in men in 2H26
Company expects cash position to fund operations into 2030, including potential VDPHL01 launch

Result Drivers
CLINICAL DEVELOPMENT COSTS - Co said higher R&D expenses were mainly due to increased clinical and development activity for VDPHL01 and higher personnel costs
COMMERCIAL READINESS COSTS - Co attributed higher G&A expenses to increased personnel costs, commercial readiness for VDPHL01 and professional fees

Company press release: ID:nBw37WCs0a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$23.50 mln
 
Q2 Income from Operations
 
-$29.55 mln
 
Q2 Operating Expenses
 
$29.55 mln
 
Q2 Pretax Loss
 
$23.50 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Veradermics, Incorporated is $167.00, about 50.8% above its August 10 closing price of $110.75

Reuters Recommended Reads
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Aug 10 - Oruka Therapeutics Q2 net loss widens on higher R&D costs
Aug 10 - Perspective Therapeutics Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)